Epidemiology, Risk Factors, Prevention, and Early Detection of Melanoma

Surgical Clinics of North America

Volumn 94, Issue 5, 2014, Pages 945-962

  Azoury, Saïd C ^a   Lange, Julie R ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Early detection; Epidemiology; Melanoma; Prevention; Risk factors; Screening

Indexed keywords

AGING; ANATOMICAL VARIATION; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; EARLY DIAGNOSIS; ECONOMIC ASPECT; EPIGENETICS; EYE COLOR; FAMILY HISTORY; HAIR COLOR; HEALTH CARE COST; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MEDICAL HISTORY; MELANOMA; MORBIDITY; OVERALL SURVIVAL; PATIENT EDUCATION; PHENOTYPE; RACE DIFFERENCE; RADIATION EXPOSURE; REVIEW; SEX DIFFERENCE; SOCIAL STATUS; ULTRAVIOLET RADIATION; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; CHILD; EARLY DETECTION; EPIDEMIOLOGY; FEMALE; GENETICS; HEALTH; INCIDENCE; INFANT; MALE; METHODOLOGY; MIDDLE AGED; MUTATION; PEDIGREE; PRECANCER; PRESCHOOL CHILD; PREVENTION; RISK FACTOR; SCREENING; SEX RATIO; SKIN TUMOR; SOCIOECONOMICS; SUNBATHING; YOUNG ADULT;

IMMUNOSUPPRESSIVE AGENT;

EARLY DETECTION; EPIDEMIOLOGY; MELANOMA; PREVENTION; RISK FACTORS; SCREENING;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; CHILD; CHILD, PRESCHOOL; EARLY DETECTION OF CANCER; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INFANT; MALE; MELANOMA; MIDDLE AGED; MUTATION; PATIENT EDUCATION AS TOPIC; PEDIGREE; PRECANCEROUS CONDITIONS; RISK FACTORS; SEX DISTRIBUTION; SKIN NEOPLASMS; SOCIOECONOMIC FACTORS; SUNBATHING; ULTRAVIOLET RAYS; WORLD HEALTH; YOUNG ADULT;

EID: 84907665315     PISSN: 00396109     EISSN: 15583171     Source Type: Journal    
DOI: 10.1016/j.suc.2014.07.013     Document Type: Review

References (113)

1. Ferlay J., Shin H.R., Bray F., et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127(12):2893-2917.
2. Siegel R., Ma J., Zou Z., et al. Cancer statistics. CA Cancer J Clin 2014, 64:9-29.
3. Available at: . Accessed November 5, 2013. http://www.seer.cancer.gov/statfacts.
4. Linos E., Swetter S.M., Cockburn M.G., et al. Increasing burden of melanoma in the United States. J Invest Dermatol 2009, 129(7):1666-1674.
5. Erdmann F., Lortet-Tieulent J., Schüz J., et al. International trends in the incidence of malignant melanoma 1953-2008-are recent generations at higher or lower risk?. Int J Cancer 2013, 132(2):385-400.
6. Armstrong B.K. Epidemiology of malignant melanoma: intermittent or total accumulated exposure to the sun?. J Dermatol Surg Oncol 1988, 14(8):835-849.
7. Sneyd M.J., Cox B. A comparison of trends in melanoma mortality in New Zealand and Australia: the two countries with the highest melanoma incidence and mortality in the world. BMC Cancer 2013, 13(1):372.
8. Coory M., Baade P., Aitken J., et al. Trends for in situ and invasive melanoma in Queensland, Australia, 1982-2002. Cancer Causes Control 2006, 17(1):21-27.
9. Jones W.O., Harman C.R., Ng A.K., et al. Incidence of malignant melanoma in Auckland, New Zealand: highest rates in the world. World J Surg 1999, 23(7):732-735.
10. Karim-Kos H.E., de Vries E., Soerjomataram I., et al. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer 2008, 44:1345-1389.
11. Geller A.C., Clapp R.W., Sober A.J., et al. Melanoma epidemic: an analysis of six decades of data from the Connecticut Tumor Registry. J Clin Oncol 2013, 31(33):4172-4178.
12. Cockburn M., Swetter S.M., Peng D., et al. Melanoma under-reporting: why does it happen, how big is the problem, and how do we fix it?. J Am Acad Dermatol 2008, 59(6):1081.
13. Hall H.I., Jamison P., Fulton J.P., et al. Reporting cutaneous melanoma to cancer registries in the United States. J Am Acad Dermatol 2004, 49(4):624-630.
14. Tsao H., Rogers G.S., Sober A.J. An estimate of the annual direct cost of treating cutaneous melanoma. J Am Acad Dermatol 1998, 38:669-680.
15. Cormier J.N., Xing Y., Ding M. Ethnic differences among patients with cutaneous melanoma. Arch Intern Med 2006, 166(17):1907-1914.
16. Wu X.C., Eide M.J., King J., et al. Racial and ethnic variations in incidence and survival of cutaneous melanoma in the United States 1999-2006. J Am Acad Dermatol 2011, 65(5):1-13.
17. Hohnheiser A.M., Gefeller O., Göhl J. Malignant melanoma of the skin: long-term follow-up and time to first recurrence. World J Surg 2011, 35(3):580-589.
18. Reed K.B., Brewer J.D., Lohse C.M., et al. Increasing incidence of melanoma among young adults: an epidemiological study in Olmsted County, Minnesota. Mayo Clin Proc 2012, 87(4):328-334.
19. Strouse J.J., Fears T.R., Tucker M.A., et al. Pediatric melanoma: risk factor and survival analysis of the Surveillance, Epidemiology and End Results database. J Clin Oncol 2005, 23(21):4735-4741.
20. Averbook B.J., Lee S.J., Delman K.A., et al. Pediatric melanoma: analysis of an international registry. Cancer 2013, 119(22):4012-4019.
21. Lange J.R., Palis B.E., Chang D.C., et al. Melanoma in children and teenagers: an analysis of patients from the National Cancer Data Base. J Clin Oncol 2007, 25:1363-1368.
22. Balch C.M., Soong S., Gershenwald J.E., et al. Age as a prognostic factor in patients with localized melanoma and regional metastases. Ann Surg Oncol 2013, 20:3961-3968.
23. Geller A.C., Miller D.R., Annas G.D., et al. Melanoma incidence and mortality among US whites, 1969-1999. JAMA 2002, 288:1719-1720.
24. Rhodes A.R., Weinstock M.A., Fitzpatrick T.B., et al. Risk factors for cutaneous melanoma. A practical method of recognizing predisposed individuals. JAMA 1987, 258:3146-3154.
25. Tucker M.A., Boice J.D., Hoffman D.A. Second cancer following cutaneous melanoma and cancers of the brain, thyroid, connective tissue, bone, and eye in Connecticut, 1935-82. Natl Cancer Inst Monogr 1985, 68:161-189.
26. Abern M.R., Tsivian M., Coogan C.L., et al. Characteristics of patients diagnosed with both melanoma and renal cell cancer. Cancer Causes Control 2013, 24(11):1925-1933.
27. Levi F., Te V.C., Randimbison L., et al. Cancer risk in women with previous breast cancer. Ann Oncol 2003, 14(1):71-73.
28. Li W.Q., Qureshi A.A., Ma J., et al. Personal history of prostate cancer and increased risk of incident melanoma in the United States. J Clin Oncol 2013, 31(35):4394-4399.
29. Pappo A.S., Armstrong G.T., Liu W., et al. Melanoma as a subsequent neoplasm in adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer 2013, 60:461-466.
30. Gandini S., Sera F., Cattaruzza M.S., et al. Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer 2005, 41:28-44.
31. Swerdlow A.J., English J.S.C., Qiao Z. The risk of melanoma in patients with congenital nevi: a cohort study. J Am Acad Dermatol 1995, 32(4):595-599.
32. Egan C.L., Oliveria S.A., Elenitsas R., et al. Cutaneous melanoma risk and phenotypic changes in large congenital nevi: a follow-up study of 46 patients. J Am Acad Dermatol 1998, 39(6):923-932.
33. Gandini S., Sera F., Cattaruzza M.S., et al. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer 2005, 41:2041-2059.
34. Yokoyama S., Woods S.L., Boyle G.M., et al. A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 2011, 480:99-103.
35. Goldstein A.M., Chan M., Harland M., et al. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet 2007, 44(2):99-106.
36. Zuo L., Weger J., Yang Q., et al. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 1996, 12(1):97-99.
37. Haluska F.G., Hodi F.S. Molecular genetics of familial cutaneous melanoma. J Clin Oncol 1998, 16(2):670-682.
38. Curtin J.A., Fridlyand J., Kageshita T., et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005, 353:2135-2147.
39. Valverde P., Healy E., Jackson I., et al. Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nat Genet 1995, 11(3):328-330.
40. Ralmondi S., Sera F., Gandini S., et al. MC1R variants, melanoma and red hair color phenotype: a meta-analysis. Int J Cancer 2008, 122:2753-2760.
41. Rigel D.S., Rivers J.K., Friedman R.J., et al. Risk gradient for malignant melanoma in individuals with dysplastic naevi. Lancet 1988, 1(8581):352-353.
42. Green M.H., Clark W.H., Tucker M.A., et al. High risk of malignant melanoma in melanoma-prone families with dysplastic nevi. Ann Intern Med 1985, 102(4):458-465.
43. Fletcher O., Easton D., Anderson K., et al. Lifetime risks of common cancers among retinoblastoma survivors. J Natl Cancer Inst 2004, 96(5):357-363.
44. Njauw C.N., Kim I., Piris A., et al. Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous-ocular melanoma families. PLoS One 2012, 7(4):335295.
45. Debniak T., Scott R.J., Górski B., et al. Common variants of DNA repair genes and malignant melanoma. Eur J Cancer 2008, 44(1):110-114.
46. Gudbjartsson D.F., Sulem P., Stacey S.N., et al. ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma. Nat Genet 2008, 40(7):886-891.
47. Paszkowska-Szczur K., Scott R.J., Serrano-Fernandez P., et al. Xeroderma pigmentosum genes and melanoma risk. Int J Cancer 2013, 133(5):1094-1100.
48. Bennett P.E., Bemis L., Norris D.A., et al. miR in melanoma development: miRNAs and acquired hallmarks of cancer in melanoma. Physiol Genomics 2013, 45:1049-1059.
49. Gandini S., Sera F., Cattaruzza M.S., et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer 2005, 41:45-60.
50. Jhappan C., Noonan F.P., Merlino G. Ultraviolet radiation and cutaneous malignant melanoma. Oncogene 2003, 22(20):3099-3112.
51. Chang Y.M., Barrett J.H., Bishop D.T., et al. Sun exposure and melanoma risk at different latitudes: a pooled analysis of 5700 cases and 7216 controls. Int J Epidemiol 2009, 38(3):814-830.
52. Hodis E., Watson I.R., Kryukov G.V., et al. A landscape of driver mutations in melanoma. Cell 2012, 150:251-263.
53. Zaidi M.R., Davis S., Noonan F.P., et al. Interferon-γ links ultraviolet radiation to melanomagenesis in mice. Nature 2011, 469(7331):548-553.
54. Berger M.F., Hodis E., Hefferman T.P., et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 2012, 485:502-506.
55. Noonan F.P., Recio J.A., Takayama H., et al. Neonatal sunburn and melanoma in mice. Nature 2001, 413(6853):271-272.
56. Gilchrest B.A., Eller M.S., Geller A.C., et al. The pathogenesis of melanoma induced by ultraviolet radiation. N Engl J Med 1999, 340(17):1341-1348.
57. Bald T., Quast T., Landsberg J., et al. Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma. Nature 2014, 507(7490):109-113.
58. Whiteman D.C., Watt P., Purdue D.M., et al. Melanocytic nevi, solar keratosis, and divergent pathways to cutaneous melanoma. J Natl Cancer Inst 2003, 95:806-812.
59. Caini S., Gandini S., Sera F., et al. Meta-analysis of risk factors for cutaneous melanoma according to anatomical site and clinico-pathological variant. Eur J Cancer 2009, 45:3054-3063.
60. Boniol M., Autier P., Boyle P., et al. Cutaneous melanoma attributable to sunbed use: systematic review and meta-analysis. BMJ 2012, 345:1-12.
61. Gandini S., Autier P., Boniol M. Reviews on sun exposure and artificial light and melanoma. Prog Biophys Mol Biol 2011, 107:362-366.
62. IARC Working Group on Artificial UV light and Skin Cancer The association of use of sunbeds with cutaneous malignant melanoma and other skin cancers: a systematic review. Int J Cancer 2007, 120:1116-1122.
63. Kwon H.T., Mayer J.A., Walker K.K., et al. Promotion of frequent tanning sessions by indoor tanning facilities: two studies. J Am Acad Dermatol 2002, 46:700-705.
64. Swerdlow A.J., Weinstock M.A. Do tanning lamps cause melanoma? An epidemiologic assessment. J Am Acad Dermatol 1998, 38:89-99.
65. Centers for Disease Control and Prevention (CDC) Use of indoor tanning devices by adults-United States, 2010. MMWR Morb Mortal Wkly Rep 2012, 61(18):323-326.
66. Héry C., Tryggvadottir L., Sigurdsson T., et al. A melanoma epidemic in Iceland: possible influence of sunbed use. Am J Epidemiol 2010, 172(7):762-767.
67. Balch C.M., Soong S.J., Gershenwald J.E., et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001, 19(6):3622-3634.
68. Finkel T., Serrano M., Blasco M.A. The common biology of cancer and ageing. Nature 2007, 448:767-774.
69. Curtis H.J. Biological mechanisms underlying the aging process. Science 1963, 141(3582):686-694.
70. Lange J.R., Kang S., Balch C.M. Melanoma in the older patient: measuring frailty as an index of survival. Ann Surg Oncol 2011, 18(12):3531-3532.
71. Tsai S., Balch C., Lange J. Epidemiology and treatment of melanoma in elderly patients. Nat Rev Clin Oncol 2010, 7(3):148-152.
72. Lindelof B., Sigurgeirsson B., Gabel H., et al. Incidence of skin cancer in 5356 patients following organ transplantation. Br J Dermatol 2000, 143:513-519.
73. DePry J.L., Reed K.B., Cook-Norris R.H., et al. Iatrogenic immunosuppression and cutaneous malignancy. Clin Dermatol 2011, 29:602-613.
74. Brewer J.D., Christenson L.J., Weaver A.L., et al. Malignant melanoma in solid transplant recipients. Arch Dermatol 2011, 147(7):790-796.
75. Pollitt R.A., Clarke C.A., Swetter S.M., et al. The expanding melanoma burden in California Hispanics: importance of socioeconomic distribution, histologic subtype, and anatomic location. Cancer 2011, 117(1):152-161.
76. Pollitt R.A., Clarke C.A., Shema S.J., et al. California Medicaid enrollment and melanoma stage at diagnosis: a population-based study. Am J Prev Med 2008, 35(1):7-13.
77. Eiser J.R., Pendry L., Greaves C.J., et al. Is targeted early detection for melanoma feasible? Self assessments of risk and attitudes to screening. J Med Screen 2000, 7:199-202.
78. Halpern M.T., Ward E.M., Pavluck A.L., et al. Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: a retrospective analysis. Lancet Oncol 2008, 9(3):222-231.
79. Reyes-Ortiz C.A., Goodwin J.S., Freeman J.L., et al. Socioeconomic status and survival in older patients with melanoma. J Am Geriatr Soc 2006, l54:1758-1764.
80. Long M.D., Martin C.F., Pipkin C.A., et al. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology 2012, 143:390-399.
81. Johannesdottir S.A., Chang E.T., Mehnert F., et al. Nonsteroidal anti-inflammatory drugs and the risk of skin cancer: a population-based case-control study. Cancer 2012, 118:4768-4776.
82. Gandini S., Iodice S., Koomen E., et al. Hormonal and reproductive factors in relation to melanoma in women: current review and meta-analysis. Eur J Cancer 2011, 47:2607-2617.
83. Sergentanis T.N., Antoniadis A.G., Gogas H.J., et al. Obesity and risk of malignant melanoma: a meta-analysis of cohort and case-control studies. Eur J Cancer 2013, 49:642-657.
84. Asgari M.M., Maruti S.S., Kushi L.H., et al. A cohort study of vitamin D intake and melanoma risk. J Invest Dermatol 2009, 129(7):1675-1680.
85. Bajaj A., Driver J.A., Schernhammer E.S. Parkinson's disease and cancer risk: a systemic review and meta-analysis. Cancer Causes Control 2010, 21:697-707.
86. Fiala K.H., Whetteckey J., Manyam B.V. Malignant melanoma and levodopa in Parkinson's disease: causality or coincidence?. Parkinsonism Relat Disord 2003, 9:321-327.
87. Liu R., Gao X., Lu Y., et al. Meta-analysis of the relationship between Parkinson disease and melanoma. Neurology 2011, 76:2002-2009.
88. Available at: . Accessed November 25, 2013. http://www.cancer.org/cancer/news/study-links-tanning-bed-use-to-increased-risk-of-melanoma.
89. Kasparian N.A., Mcloone J.K., Meiser B. Skin cancer-related prevention and screening behaviors: a review of the literature. J Behav Med 2009, 32(5):406-428.
90. Green A.C., Williams G.M., Logan V., et al. Reduced melanoma after regular sunscreen use: randomized trial follow-up. J Clin Oncol 2011, 29(3):257-263.
91. Moyer V.A., U.S.Preventive Services Task Force Behavioral counseling to prevent skin cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012, 157(1):59-65.
92. Lin J.S., Eder M., Weinmann S. Behavioral counseling to prevent skin cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2011, 154(3):190-201.
93. International Commission on Non-Ionizing Radiation Protection (ICNIRP) Health issues of ultraviolet tanning appliances used for cosmetic purposes. Health Phys 2003, 84(1):119-127.
94. Available at: . Accessed March 5, 2014. http://www.who.int/uv/publications/en/sunbeds.pdf?ua=1.
95. Geller A.C., Balk S.J., Fisher D.E. Stemming the tanning bed epidemic: time for action. J Natl Compr Canc Netw 2012, 10(10):1311-1314.
96. Available at: . Accessed March 25, 2014. http://www.cancer.org/cancer/cancercauses/sunanduvexposure/skincancerpreventionandearlydetection/skin-cancer-prevention-and-early-detection-skin-exams.
97. Schwartz J.L., Wang T.S., Hamilton T.A., et al. Thin primary cutaneous melanomas: associated detection patterns, lesion characteristics, and patient characteristics. Cancer 2002, 95(7):1562-1568.
98. Abbasi N.R., Shaw H.M., Rigel D.S., et al. Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria. JAMA 2004, 292(22):2771-2776.
99. Friedman R.J., Rigel D.S., Kopf A.W. Early detection of malignant melanoma: the role of physician examination and self-examination of the skin. CA Cancer J Clin 1985, 35:130-151.
100. Wood B.A. Desmoplastic melanoma: recent advances and persisting challenges. Pathology 2013, 45(5):453-463.
101. Rigel D.S., Russak J., Friedman R. The evolution of melanoma diagnosis: 25 years beyond the ABCDs. CA Cancer J Clin 2010, 60:301-316.
102. Geller A.C. Educational and screening campaigns to reduce deaths from melanoma. Hematol Oncol Clin North Am 2009, 23:515-527.
103. Losina E., Walensky R.P., Geller A., et al. Visual screening for malignant melanoma: a cost-effectiveness analysis. Arch Dermatol 2007, 143(1):21-28.
104. Epstein D.S., Lange J.R., Gruber S.B., et al. Is physician detection association with thinner melanomas?. JAMA 1999, 281(7):640-643.
105. Brady M.S., Oliveria S.A., Christos P.J., et al. Patterns of detection in patients with cutaneous melanoma. Cancer 2000, 89(2):342-347.
106. Geller A.C., O'Riordan D.L., Oliveria S.A., et al. Overcoming obstacles to skin cancer examinations and prevention counseling for high-risk patients: results of a national survey of primary care physicians. J Am Board Fam Pract 2004, 17(6):416-423.
107. Geller A.C., Swetter S.M., Oliveria S., et al. Reducing mortality in individuals at high risk for advanced melanoma through education and screening. J Am Acad Dermatol 2011, 65(5):1-69.
108. Institute of Medicine Extending Medicare coverage for prevention and other services 2000, National Academy Press, Washington, DC.
109. U.S.Preventive Services Task Force Screening for skin cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009, 150(3):188-193.
110. Geller A.C., Zhang Z., Sober A.J., et al. The first 15 years of the American Academy of Dermatology skin cancer screening programs: 1985-1999. J Am Acad Dermatol 2003, 48(1):34-41.
111. Katalinic A., Waldmann A., Weinstock M.A., et al. Does skin cancer screening save lives? An observational study comparing trends in melanoma mortality in regions with and without screening. Cancer 2012, 118:5395-5402.
112. Aitken J.F., Elwood M., Baade P.D., et al. Clinical whole-body skin examination reduces the incidence of thick melanomas. Int J Cancer 2010, 126:450-458.
113. Geller A.C., Elwood M., Swetter S.M., et al. Factors related to the presentation of thin and thick nodular melanoma from a population-based cancer registry in Queensland Australia. Cancer 2009, 115:1318-1327.